CD44 and hepatocellular carcinoma: In hepatocellular carcinoma (HCC), 71.4% of HCC patients were CTC positive for the cancer stem cell marker, CD44; thus, they had a significant population of CTCs with stem properties, which could contribute to tumor cell survival and dissemination116.